Hi, what are you looking for?
Impax, Stada, Taro may be takeover targets for Mylan, Perrigo; Mylan may also look for assets shed in Teva-Allergan deal
Mylan's Executive Chairman Robert Coury: we are well-positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we...
Generic drug maker Mylan $26bn hostile bid for peer Perrigo looked unlikely to succeed, a few hours before it was set to expire, a...
Perrigo Company Plc, the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV, held unsuccessful talks to acquire Endo International...
Mylan begins trading on the TASE; agrees to sell rights and assets related to seven generic drugs to secure regulatory approval of its hostile...
Regulator tells Migdal Insurance to rescind giant dividend; Noble Energy posts wider-than-expected loss for the third quarter; Pharma, telecom shares lead Tel Aviv higher.
Court rules that Mylan provided adequate public disclosures.
6% workforce reduction, $2 billion in stock repurchases and vitamin unit sale in the offing
The hostile takeover bid for Perrigo Co. PLC continues with Mylan NV hosting a Tuesday, 5 pm, conference call to pitch the buyout...
The Generic-drug maker took its bid directly to shareholders after being rebuffed since April